A Phase 3 Matrix Design Partially Double-Blind Randomized Study of the Efficacy and Safety of 50 mg Lonafarnib/100 mg Ritonavir BID with and without 180 mcg PEG IFN-alfa-2a for 48 Weeks Compared with PEG IFN-alfa-2a Monotherapy and Placebo Treatment in Patients Chronically Infected with Hepatitis Delta Virus Being Maintained on Anti-HBV Nucleos(t)ide Therapy (D-LIVR)

Brief description of study

Although there is no preventative vaccine or approved treatment for HDV, researchers are studying new treatments for HDV. This research study is designed to learn more about the effectiveness and safety of an investigational drug called lonafarnib that is being developed to treat chronic HDV infection as well as other conditions. Investigational means lonafarnib is not approved by regulatory authorities, including the United States (US) Food and Drug Administration (FDA), for prescription or over-the-counter (OTC) use. Other purposes of this study are to determine whether the study drugs will reduce the amount of HDV in your blood, determine the effects of the study drugs on your liver and to determine if taking the study drugs makes your quality of life better.


Clinical Study Identifier: s18-01174
Principal Investigator: Viviana Figueroa Diaz
Currently Recruiting

Contact the research team to learn more about this study.


By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.